50 results on '"Marcocci, C"'
Search Results
2. Clinical and molecular characteristics of two Italian kindreds with hypoparathyroidism, deafness and renal dysplasia (HDR) syndrome.
3. Conventional X-rays in the diagnosis and follow-up of vertebral fractures in patients with acromegaly: a real-life study.
4. In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features.
5. Anti-nuclear autoantibodies in Graves' disease and Graves' orbitopathy.
6. Sirolimus as a second-line treatment for Graves' orbitopathy.
7. Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism.
8. Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment.
9. Role of the mononuclear cell infiltrate in Graves' orbitopathy (GO): results of a large cohort study.
10. Renal complications and quality of life in postsurgical hypoparathyroidism: a case–control study.
11. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
12. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
13. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
14. Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?
15. Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.
16. Consensus statement from 2nd International Conference on Controversies in Vitamin D.
17. Whole exome sequencing in familial isolated primary hyperparathyroidism.
18. Macro-PTH, a rare cause of unexplained elevated serum PTH levels.
19. Vitamin D status and cardiovascular outcome.
20. Measurement of urinary free cortisol by LC–MS–MS: adoption of a literature reference range and comparison with our current immunometric method.
21. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
22. Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic.
23. Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study.
24. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism.
25. Rehabilitative orbital decompression for Graves’ orbitopathy: results of a randomized clinical trial.
26. Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO).
27. Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients.
28. Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?
29. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.
30. Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.
31. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
32. Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial.
33. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
34. Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
35. Update on parathyroid carcinoma.
36. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.
37. Total thyroid ablation in Graves' orbitopathy.
38. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
39. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
40. Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.
41. Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement.
42. Graves' disease and Graves' orbitopathy following COVID-19.
43. Multidetector CT in diagnostic work-up of patients with primary hyperparathyroidism.
44. Occurrence of Graves' hyperthyroidism and Graves' orbitopathy after fine-needle aspiration biopsy of thyroid nodules.
45. Usefulness of echo-color Doppler in differentiating parathyroid lesions from other cervical masses.
46. Acute severe primary hyperparathyroidism: spontaneous remission after 2 years follow-up.
47. Correction to: Whole exome sequencing in familial isolated primary hyperparathyroidism.
48. Familial hypocalciuric hypercalcemia type 1 due to a novel homozygous mutation of the calcium-sensing receptor gene.
49. A large functioning parathyroid lipoadenoma.
50. Effects of thyroid hormone treatment on bone mass and bone turnover: Prospective studies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.